We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Adobe, Pfizer, Intel and T-Mobile US
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 30, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Incorporated (UNH - Free Report) , Adobe Inc. (ADBE - Free Report) , Pfizer Inc. (PFE - Free Report) , Intel Corporation (INTC - Free Report) and T-Mobile US, Inc. (TMUS - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for UnitedHealth, Adobe and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, Adobe and Pfizer. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
UnitedHealth shares have outperformed the Zacks Medical Insurance industry in the year to date period (+2.9% vs. -2%). The Zacks analyst believes that its numerous acquisitions bode well for its inorganic growth profile. Further, expansion of its health services segment provides significant diversification benefits.
A solid balance sheet and consistent cash flow generation not only encourage investments in business but also add shareholder value. The company’s top line has been bolstered by new deals, renewed agreements and expansion of service offerings.
It's third-quarter earnings of $3.51 per share beat estimates by 17.8%, but declined 9.5% year over year as the pandemic-disrupted healthcare utilization returned closer to normalcy. However, it is witnessing a slowdown in its international operations. Commercial membership may also see attrition due to increased joblessness.
Shares of Adobe have gained +65.9% over the past year against the Zacks Computer Software industry’s rise of +31%. The Zacks analyst believes Adobe is gaining from strong demand for its creative products. The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth.
Further, rising subscription revenues and solid momentum across mobile apps are major positives. Additionally, growth in emerging markets, robust online video creation demand and improving average revenue per user are tailwinds. We remain optimistic about Adobe’s market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and Adobe marketing cloud.
However, lower end-market demand is a concern. Further, significant exposure in Europe is an overhang due to foreign currency headwinds. Additionally, high acquisition expenses do not bode well for margin expansion.
Pfizer’s shares have lost -8.8% over the past six months against the Zacks Large-Cap Pharmaceuticals industry’s fall of -6.1%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo and the pending merger of Upjohn unit with Mylan will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
The smaller Pfizer should see better revenue growth as the Lyrica loss of exclusivity (LOE) cliff will go away. Pfizer expects strong growth of key brands like Ibrance and Eliquis to drive sales in future quarters. The focus remains on the progress of its COVID-19 vaccine.
Pfizer beat Q3 estimates for earnings while missing the same for sales. It narrowed its 2020 guidance due to a slow pace of recovery from pandemic. However, currency headwinds and pricing pressure are key top-line headwinds. Coronavirus-related business disruption hurt sales in Q2 and Q3.
Other noteworthy reports we are featuring today include Intel and T-Mobile US.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: UnitedHealth Group, Adobe, Pfizer, Intel and T-Mobile US
For Immediate Release
Chicago, IL – October 30, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Incorporated (UNH - Free Report) , Adobe Inc. (ADBE - Free Report) , Pfizer Inc. (PFE - Free Report) , Intel Corporation (INTC - Free Report) and T-Mobile US, Inc. (TMUS - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for UnitedHealth, Adobe and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, Adobe and Pfizer. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
UnitedHealth shares have outperformed the Zacks Medical Insurance industry in the year to date period (+2.9% vs. -2%). The Zacks analyst believes that its numerous acquisitions bode well for its inorganic growth profile. Further, expansion of its health services segment provides significant diversification benefits.
A solid balance sheet and consistent cash flow generation not only encourage investments in business but also add shareholder value. The company’s top line has been bolstered by new deals, renewed agreements and expansion of service offerings.
It's third-quarter earnings of $3.51 per share beat estimates by 17.8%, but declined 9.5% year over year as the pandemic-disrupted healthcare utilization returned closer to normalcy. However, it is witnessing a slowdown in its international operations. Commercial membership may also see attrition due to increased joblessness.
(You can read the full research report on UnitedHealth here >>>)
Shares of Adobe have gained +65.9% over the past year against the Zacks Computer Software industry’s rise of +31%. The Zacks analyst believes Adobe is gaining from strong demand for its creative products. The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth.
Further, rising subscription revenues and solid momentum across mobile apps are major positives. Additionally, growth in emerging markets, robust online video creation demand and improving average revenue per user are tailwinds. We remain optimistic about Adobe’s market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and Adobe marketing cloud.
However, lower end-market demand is a concern. Further, significant exposure in Europe is an overhang due to foreign currency headwinds. Additionally, high acquisition expenses do not bode well for margin expansion.
(You can read the full research report on Adobe here >>>)
Pfizer’s shares have lost -8.8% over the past six months against the Zacks Large-Cap Pharmaceuticals industry’s fall of -6.1%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo and the pending merger of Upjohn unit with Mylan will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
The smaller Pfizer should see better revenue growth as the Lyrica loss of exclusivity (LOE) cliff will go away. Pfizer expects strong growth of key brands like Ibrance and Eliquis to drive sales in future quarters. The focus remains on the progress of its COVID-19 vaccine.
Pfizer beat Q3 estimates for earnings while missing the same for sales. It narrowed its 2020 guidance due to a slow pace of recovery from pandemic. However, currency headwinds and pricing pressure are key top-line headwinds. Coronavirus-related business disruption hurt sales in Q2 and Q3.
(You can read the full research report on Pfizer here >>>)
Other noteworthy reports we are featuring today include Intel and T-Mobile US.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.